

Erwin F Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1375718/publications.pdf>

Version: 2024-02-01

77
papers

14,225
citations

53751

45
h-index

74108

75
g-index

80
all docs

80
docs citations

80
times ranked

21963
citing authors

#	ARTICLE	IF	CITATIONS
1	Signal integration by JNK and p38 MAPK pathways in cancer development. <i>Nature Reviews Cancer</i> , 2009, 9, 537-549.	12.8	2,122
2	AP-1: a double-edged sword in tumorigenesis. <i>Nature Reviews Cancer</i> , 2003, 3, 859-868.	12.8	1,867
3	A Validated Regulatory Network for Th17 Cell Specification. <i>Cell</i> , 2012, 151, 289-303.	13.5	1,010
4	Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. <i>Nature</i> , 2005, 437, 369-375.	13.7	538
5	A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. <i>Cell Metabolism</i> , 2014, 20, 433-447.	7.2	535
6	Fos/AP-1 proteins in bone and the immune system. <i>Immunological Reviews</i> , 2005, 208, 126-140.	2.8	457
7	Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. <i>Nature Genetics</i> , 2000, 24, 184-187.	9.4	447
8	Liver Tumor Development. <i>Cell</i> , 2003, 112, 181-192.	13.5	445
9	JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells. <i>Cell</i> , 2004, 119, 431-443.	13.5	384
10	NF- κ B p50 and p52 Regulate Receptor Activator of NF- κ B Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1. <i>Journal of Biological Chemistry</i> , 2007, 282, 18245-18253.	1.6	364
11	Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. <i>Nature Medicine</i> , 1999, 5, 314-319.	15.2	348
12	p38 β suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. <i>Nature Genetics</i> , 2007, 39, 741-749.	9.4	342
13	Impaired Long-Term Memory and NR2A-Type NMDA Receptor-Dependent Synaptic Plasticity in Mice Lacking c-Fos in the CNS. <i>Journal of Neuroscience</i> , 2003, 23, 9116-9122.	1.7	321
14	Mechanisms of metabolic dysfunction in cancer-associated cachexia. <i>Genes and Development</i> , 2016, 30, 489-501.	2.7	239
15	Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. <i>EMBO Journal</i> , 2002, 21, 1782-1790.	3.5	234
16	JunB is essential for mammalian placentation. <i>EMBO Journal</i> , 1999, 18, 934-948.	3.5	232
17	Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. <i>Nature Cell Biology</i> , 2012, 14, 1203-1211.	4.6	218
18	Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage. <i>Cell</i> , 2001, 104, 21-32.	13.5	215

#	ARTICLE	IF	CITATIONS
19	S100A8-S100A9 Protein Complex Mediates Psoriasis by Regulating the Expression of Complement Factor C3. <i>Immunity</i> , 2013, 39, 1171-1181.	6.6	205
20	C-Jun N-terminal Kinase (Jnk)1 and Jnk2 Have Similar and Stage-Dependent Roles in Regulating T Cell Apoptosis and Proliferation. <i>Journal of Experimental Medicine</i> , 2001, 193, 317-328.	4.2	199
21	Psoriasis: what we have learned from mouse models. <i>Nature Reviews Rheumatology</i> , 2010, 6, 704-714.	3.5	190
22	Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. <i>Journal of Cell Biology</i> , 2004, 164, 613-623.	2.3	188
23	Promoter Specificity and Biological Activity of Tethered AP-1 Dimers. <i>Molecular and Cellular Biology</i> , 2002, 22, 4952-4964.	1.1	171
24	Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10525-10530.	3.3	163
25	Calprotectin: from biomarker to biological function. <i>Gut</i> , 2021, 70, 1978-1988.	6.1	163
26	Inhibition of De Novo NAD + Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage. <i>Cancer Cell</i> , 2014, 26, 826-839.	7.7	162
27	Mouse models for liver cancer. <i>Molecular Oncology</i> , 2013, 7, 206-223.	2.1	144
28	Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 21264-21269.	3.3	135
29	Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. <i>Science Translational Medicine</i> , 2016, 8, 330ra37.	5.8	133
30	JunB can substitute for Jun in mouse development and cell proliferation. <i>Nature Genetics</i> , 2002, 30, 158-166.	9.4	132
31	Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 1043-1049.	1.2	131
32	Targeting miR-21 to Treat Psoriasis. <i>Science Translational Medicine</i> , 2014, 6, 225re1.	5.8	123
33	Fos and Jun Proteins Are Specifically Expressed During Differentiation of Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2005, 124, 212-220.	0.3	109
34	Regulation of Steatohepatitis and PPAR β Signaling by Distinct AP-1 Dimers. <i>Cell Metabolism</i> , 2014, 19, 84-95.	7.2	99
35	Specific roles for dendritic cell subsets during initiation and progression of psoriasis. <i>EMBO Molecular Medicine</i> , 2014, 6, 1312-1327.	3.3	92
36	c-Jun Controls Histone Modifications, NF- κ B Recruitment, and RNA Polymerase II Function To Activate the ccl2 Gene. <i>Molecular and Cellular Biology</i> , 2008, 28, 4407-4423.	1.1	83

#	ARTICLE	IF	CITATIONS
37	Essential role of RSK2 in c-Fos-dependent osteosarcoma development. <i>Journal of Clinical Investigation</i> , 2005, 115, 664-672.	3.9	81
38	Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. <i>Journal of Experimental Medicine</i> , 2017, 214, 1387-1409.	4.2	80
39	Rhabdomyosarcoma development in mice lacking Trp53 and Fos. <i>Cancer Cell</i> , 2003, 4, 477-482.	7.7	68
40	Wnt signaling and Loxl2 promote aggressive osteosarcoma. <i>Cell Research</i> , 2020, 30, 885-901.	5.7	68
41	Fra-2-expressing macrophages promote lung fibrosis. <i>Journal of Clinical Investigation</i> , 2019, 129, 3293-3309.	3.9	67
42	Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17105-17110.	3.3	64
43	Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis. <i>Journal of Experimental Medicine</i> , 2001, 193, 353-364.	4.2	59
44	Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20423-20428.	3.3	58
45	Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. <i>Genes and Development</i> , 2013, 27, 1959-1973.	2.7	53
46	Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17582-17587.	3.3	45
47	Essential role of RSK2 in c-Fos-dependent osteosarcoma development. <i>Journal of Clinical Investigation</i> , 2005, 115, 664-672.	3.9	45
48	JUNB/AP-1 controls IFN- β during inflammatory liver disease. <i>Journal of Clinical Investigation</i> , 2013, 123, 5258-5268.	3.9	44
49	Psoriatic skin inflammation is promoted by c-Jun/AP-1-dependent CCL2 and IL-23 expression in dendritic cells. <i>EMBO Molecular Medicine</i> , 2021, 13, e12409.	3.3	42
50	Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. <i>Nature Cell Biology</i> , 2008, 10, 1003-1011.	4.6	41
51	Stable murine chondrogenic cell lines derived from c-fos-induced cartilage tumors. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 839-847.	3.1	35
52	A waste of insulin interference. <i>Nature</i> , 2015, 521, 430-431.	18.7	34
53	An immune-sympathetic neuron communication axis guides adipose tissue browning in cancer-associated cachexia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
54	Fra-1 substitutes for c-Fos in AP-1-mediated signal transduction in retinal apoptosis. <i>Journal of Neurochemistry</i> , 2002, 80, 1089-1094.	2.1	27

#	ARTICLE	IF	CITATIONS
55	Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment. <i>Cancer Research</i> , 2021, 81, 968-985.	0.4	27
56	Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. <i>Bone</i> , 2007, 40, 867-875.	1.4	26
57	Activator protein 1 transcription factor fos-related antigen 1 (fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. <i>Hepatology</i> , 2014, 59, 261-273.	3.6	25
58	Signalling in inflammatory skin disease by AP-1 (Fos/Jun). <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S44-9.	0.4	25
59	EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	24
60	Simultaneous generation of <i>fra1</i> ^{Cre} conditional and <i>fra1</i> ^{Cre} knock-out mice. <i>Genesis</i> , 2007, 45, 447-451.	0.8	23
61	Role of IL-17A signalling in psoriasis and associated bone loss. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 17-20.	0.4	23
62	In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. <i>Oncogene</i> , 2021, 40, 2437-2447.	2.6	21
63	Chronic systemic inflammation originating from epithelial tissues. <i>FEBS Journal</i> , 2017, 284, 505-516.	2.2	19
64	JunB is a key regulator of multiple myeloma bone marrow angiogenesis. <i>Leukemia</i> , 2021, 35, 3509-3525.	3.3	19
65	The AP-1 transcription factors c-Jun and JunB are essential for CD8 ⁺ conventional dendritic cell identity. <i>Cell Death and Differentiation</i> , 2021, 28, 2404-2420.	5.0	18
66	Role of bulge epidermal stem cells and TSLP signaling in psoriasis. <i>EMBO Molecular Medicine</i> , 2019, 11, e10697.	3.3	17
67	Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model. <i>Experimental Dermatology</i> , 2021, 30, 1662-1674.	1.4	16
68	Cutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB/AP-1. <i>Cell Reports</i> , 2019, 29, 844-859.e3.	2.9	13
69	Targeting AP-1 transcription factors by CRISPR in the prostate. <i>Oncotarget</i> , 2021, 12, 1956-1961.	0.8	11
70	Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1400-1408.	0.5	11
71	Sequestosome 1/p62 enhances chronic skin inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2386-2393.e4.	1.5	10
72	Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration. <i>Journal of Visualized Experiments</i> , 2018, . .	0.2	8

#	ARTICLE	IF	CITATIONS
73	Syndecan-1 shedding by mepirin \hat{I}^2 impairs keratinocyte adhesion and differentiation in hyperkeratosis. Matrix Biology, 2021, 102, 37-69.	1.5	6
74	TPL-2 Inhibits IFN- \hat{I}^2 Expression via an ERK1/2-TCF-FOS Axis in TLR4-Stimulated Macrophages. Journal of Immunology, 2022, 208, 941-954.	0.4	3
75	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. Blood, 2019, 134, 4341-4341.	0.6	0
76	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myeloma Therapy. Blood, 2019, 134, 4415-4415.	0.6	0
77	Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. Blood, 2021, 138, 2644-2644.	0.6	0